Attention has turned to a developing story after scientists have come up with encouraging results of a drug for people suffering from severe hair loss, which regrowed all the hair on the scalp in some patients. In alopecia areata, the body's immune system mistakenly targets the hair follicles, resulting in massive hair loss.

Highlights

Tracing the events that led here provides important context for what follows.

Hair roots are not permanently destroyed in this disease, but the real challenge is to stop this strike by the immune system.

There are limited effective treatments for this disease, especially for young people.

Observers have also noted that a new study evaluated a drug used to treat joint pain and body inflammation in patients with severe hair loss.

Standout Performances

Those following the situation closely say this marks a meaningful shift.

A total of 1,399 people between the ages of 12 and 64 participated in two separate but concurrent clinical trials.

Compounding the significance of these events, they were given different doses of the drug or an inactive pill daily for 24 weeks.

What has become increasingly clear is that about 54 and 55 percent of the high-dose patients achieved this goal during the two trials, respectively.

Numbers

The downstream effects of this situation are being assessed by officials and experts alike.

Among patients taking the low dose, the rate was about 45 percent, while among those taking the inactive pill, the rate was only between one and a half to three and a half percent.

As the story continues to develop, according to research, the effect of the drug started to be noticeable only eight weeks after the start of treatment.

Notably, according to the researchers, an improvement was also observed in the quality of life of the patients and the mental and emotional stress caused by the disease.

At the same time, that said, experts caution that the trials only lasted 24 weeks, so more research is needed into the drug's long-term effects and potential risks.

Reports further indicate that the research costs were provided by the drug company and certain of the researchers are also affiliated with the same company, so according to experts, the efficacy of the drug can only be determined after more trials compared to the current treatment.

Looking Ahead

Key actors in this story have not yet issued final statements, and the situation remains fluid. Updates will be reported as they become available, with the expectation that more information will emerge soon.